Home Cart Sign in  
Chemical Structure| 751-03-1 Chemical Structure| 751-03-1

Structure of Obacunone
CAS No.: 751-03-1

Chemical Structure| 751-03-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Obacunone, a natural product isolated and purified from the barks of Phellodendron chinense, has cytotoxicity in androgen-dependent human prostate cancer cells. Obacunone may have the potential to prevent estrogen-responsive breast cancer through inhibition of the aromatase enzyme and inflammatory pathways, as well as activation of apoptosis.

Synonyms: AI3-37934; CCRIS 8657

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Obacunone

CAS No. :751-03-1
Formula : C26H30O7
M.W : 454.51
SMILES Code : CC1([C@]([C@](C=CC(O1)=O)([C@@]([C@@]23C)([H])CC[C@@]([C@](O4)([H])C5=COC=C5)([C@]36[C@@](O6)([H])C4=O)C)C)([H])CC2=O)C
Synonyms :
AI3-37934; CCRIS 8657
MDL No. :MFCD00075888
InChI Key :MAYJEFRPIKEYBL-OASIGRBWSA-N
Pubchem ID :119041

Safety of Obacunone

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • Aromatase

    Aromatase, IC50:28.4 μM

In Vitro:

Cell Line
Concentration Treated Time Description References
Mature osteoclasts 20 μM To evaluate the effect of OB on the morphological changes of osteoclasts. Results showed that OB-treated groups had significantly reduced osteoclast area and number of nuclei. PMC10658311
Bone marrow macrophages (BMMs) 0, 1, 5, 10, 20 μM 6 days To evaluate the inhibitory effect of OB on RANKL-induced osteoclast differentiation. Results showed that OB dose-dependently inhibited osteoclast formation. PMC10658311
Bone marrow macrophages (BMMs) 0, 1, 5, 10, 20 μM 48 h To evaluate the cytotoxicity of OB on BMMs. Results showed that OB had little effect on BMMs proliferation at the tested concentrations. PMC10658311
BEAS-2B cells 10, 20, 40 μM 4 h To evaluate the protective effects of OB against LPS-induced BEAS-2B cell injury. Results showed that OB increased cell viability and inhibited LDH release in a dose-dependent manner, and reduced the secretion of inflammatory cytokines IL-1β, IL-6, and TNF-α. PMC8933916
Madin-Darby canine kidney (MDCK) cells 3.12, 12.5, 50 μM 6 days Obacunone significantly inhibited cyst formation and expansion of MDCK cysts in a dose-dependent manner. PMC8773305
NCM460 human colonic epithelial cells 0–100 μM 24 h Evaluate the effect of obacunone on cell viability, results showed obacunone markedly increased cell viability PMC7136403
RAW264.7 mouse macrophage cells 0–100 μM 24 h Evaluate the effect of obacunone on LPS-stimulated NO production, results showed obacunone significantly suppressed NO production PMC7136403
RAW264.7 mouse macrophage cells 0–100 μM 24 h Evaluate the effect of obacunone on cell viability, results showed almost no cytotoxicity at concentrations up to 100 μM PMC7136403
Caco-2 cells 100 μg/ml 3 h To evaluate the effect of Obacunone on Salmonella adhesion and invasion. Results showed that Obacunone significantly reduced the number of adherent and invasive Salmonella cells. PMC3457478

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
B6 mice Bleomycin-induced lung fibrosis model Intraperitoneal injection 10 mg/kg Detected after 48 hours Obacunone inhibits bleomycin-induced lung fibrosis by activating the Nrf2 pathway PMC5003787
C57BL/6J female mice Ovariectomy-induced osteoporosis model Intraperitoneal injection 5 mg/kg Every two days for six weeks To evaluate the therapeutic effect of OB on ovariectomy-induced osteoporosis. Results showed that OB treatment significantly prevented bone loss and inhibited osteoclast activity. PMC10658311
C57BL/6 mice LPS-induced acute lung injury model Intraperitoneal injection 2.5, 5, 10 mg/kg 48 hours To evaluate the protective effects of OB against LPS-induced acute lung injury. Results showed that OB significantly alleviated LPS-induced lung histopathological injury, reduced inflammatory cytokine secretion and Fe2+ and 4-HNE levels, and upregulated GPX4, SLC7A11, and Nrf2 expression. PMC8933916
Mice Kidney-specific Pkd1 knockout mouse (PKD) model Intraperitoneal injection 100 mg/kg Once daily for 4 days Obacunone significantly retarded renal cyst development in PKD mice. PMC8773305
C57BL/6 mice CFA-induced inflammatory pain model Intraperitoneal injection 10 mg/kg Once daily for three consecutive days OB alleviates inflammatory pain by promoting microglial polarization from M1 to M2 and activating the Nrf2/HO-1 signaling pathway. PMC11034512
C57BL/6 mice DSS-induced ulcerative colitis model Oral gavage 25, 50, 100 mg/kg/day Once daily, starting from 2 days before DSS treatment and continuing to the end of the experiment Evaluate the protective effect of obacunone on DSS-induced colitis, results showed obacunone significantly attenuated disease symptoms including weight loss, diarrhea, bloody stool, and colonic shortening PMC7136403

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.20mL

0.44mL

0.22mL

11.00mL

2.20mL

1.10mL

22.00mL

4.40mL

2.20mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories